Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL)

Karen A. Urtishak, PhD, Wang Li-San, PhD, David T. Teachey, MD, Tasian K. Sarah, MD, Jeffrey S. Barrett, PhD, I-Ming L. Chen, Susan R. Atlas, PhD, Richard C. Harvey, PhD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Stephen P. Hunger, MD, Cheryl L. Willman, MD, Carolyn A. Felix, MD

Blood (2013) 122 (21): 1669.

https://doi.org/10.1182/blood.V122.21.1669.1669

Published: 2013

Journal Articles

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia

Blood (2013) 121 (14): 2689–2703.

https://doi.org/10.1182/blood-2012-04-425033

Published: 2013

Includes: Supplemental data

Journal Articles

Predicting Clinical Dose-Exposure and Exposure-Response Relationships of Pan-Antiapoptotic BCL-2 Family Inhibitor Obatoclax in MLL Rearranged Infant Leukemias From Preclinical Disease Models and Adult Experience

Jeffrey S Barrett, PhD, Alena Y. Zhang, PhD, Karen A. Urtishak, PhD, Gwenn Danet-Desnoyers, PhD, Andrew J. Carroll, PhD, Stephen P. Hunger, MD, Carolyn A. Felix, MD

Blood (2011) 118 (21): 2580.

https://doi.org/10.1182/blood.V118.21.2580.2580

Published: 2011

Journal Articles

Population Pharmacokinetics of Enoxaparin in Children at Risk for Symptomatic Thromboembolism.

Mirjam Nadine Trame, Lesley Mitchell, MSc, Christoph Male, MD, MSC, Jeffrey S. Barrett, PhD, Georg Hempel, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 1071.

https://doi.org/10.1182/blood.V114.22.1071.1071

Published: 2009

Journal Articles

Pan-Anti-Apoptotic BCL-2 Family Inhibitor, Obatoclax, Activates Autophagic Cell Death Pathway and Has Potent Cytotoxicity in Infant and Pediatric MLL -Rearranged Leukemias

Alena Y. Zhang, PharmD, PhD, Blaine W. Robinson, PhD, Li-San Wang, PhD, Kajia Kao, PhD, Lori Cory, Jeffrey S. Barrett, PhD, Susan Atlas, PhD, I-Ming Chen, MS, Richard C. Harvey, PhD, Cheryl L. Willman, MD, Meenakshi Devidas, PhD, Andrew J. Carroll, PhD, Stephen P. Hunger, MD, Jonni S. Moore, PhD, Craig B. Thompson, MD, Mondira Kundu, MD, PhD, Carolyn A. Felix, MD

Blood (2008) 112 (11): 2647.

https://doi.org/10.1182/blood.V112.11.2647.2647

Published: 2008

Journal Articles

Pan-BCL-2 Family Small Molecule Inhibitor GX015-070 (GeminX, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations.

Jessicca M. Rege, PhD, Blaine W. Robinson, PhD, Manish Gupta, PhD, Jeffrey S. Barrett, PhD, Peter C. Adamson, MD, Kathryn C. Behling, MD, PhD, Andrew D. Bantly, Jonni S. Moore, PhD, Carolyn A. Felix, MD

Blood (2005) 106 (11): 3368.

https://doi.org/10.1182/blood.V106.11.3368.3368

Published: 2005

Journal Articles

Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense TM (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations.

Blaine W. Robinson, PhD, Kathyrn C. Behling, MD, PhD, Jeffrey S. Barrett, PhD, Manish Gupta, PhD, Jessicca M. Rege, PhD, Jonni S. Moore, PhD, Andrew D. Bantly, Junhyong Kim, PhD, George Hii, Cheryl L. Willman, MD, Jeffrey Potter, Peter C. Adamson, MD, Carolyn A. Felix, MD

Blood (2005) 106 (11): 3360.

https://doi.org/10.1182/blood.V106.11.3360.3360

Published: 2005

NARROW

PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL)

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia

Predicting Clinical Dose-Exposure and Exposure-Response Relationships of Pan-Antiapoptotic BCL-2 Family Inhibitor Obatoclax in MLL Rearranged Infant Leukemias From Preclinical Disease Models and Adult Experience

Population Pharmacokinetics of Enoxaparin in Children at Risk for Symptomatic Thromboembolism.

Pan-Anti-Apoptotic BCL-2 Family Inhibitor, Obatoclax, Activates Autophagic Cell Death Pathway and Has Potent Cytotoxicity in Infant and Pediatric MLL -Rearranged Leukemias

Pan-BCL-2 Family Small Molecule Inhibitor GX015-070 (GeminX, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations.

Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense TM (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations.

Email alerts

ASH Publications

American Society of Hematology

PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL)

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia

Predicting Clinical Dose-Exposure and Exposure-Response Relationships of Pan-Antiapoptotic BCL-2 Family Inhibitor Obatoclax in MLL Rearranged Infant Leukemias From Preclinical Disease Models and Adult Experience

Population Pharmacokinetics of Enoxaparin in Children at Risk for Symptomatic Thromboembolism.

Pan-Anti-Apoptotic BCL-2 Family Inhibitor, Obatoclax, Activates Autophagic Cell Death Pathway and Has Potent Cytotoxicity in Infant and Pediatric MLL -Rearranged Leukemias

Pan-BCL-2 Family Small Molecule Inhibitor GX015-070 (GeminX, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations.

Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense TM (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only